Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma
Background
Advanced clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer for which long-term survival rates are abysmal, though immunotherapies are showing potential. Not yet clinically vetted are bispecific T cell engagers (BTEs) that…